Polaryx Therapeutics, Inc. PLYX Indefinite-Lived Research and Development Assets
Indefinite-Lived Research and Development Assets at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.
The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Polaryx Therapeutics, Inc. 's indefinite-lived research and development assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Polaryx Therapeutics, Inc. 's indefinite-lived research and development assets?
- Polaryx Therapeutics, Inc. (PLYX) reported indefinite-lived research and development assets of $998K in Q4 2025.
- What does indefinite-lived research and development assets mean?
- Indefinite-lived R&D assets represent acquired in-process research and development (IPR&D) that is not yet ready for commercial use. Because these assets have no defined useful life until the underlying project is completed or abandoned, they are not amortized but are instead tested annually for impairment. This metric highlights the value of the company's pipeline and its investment in future growth.